New publication in The Journal of Headache and Pain
PN6047 publication in The Journal of Headache and Pain strengthens PN6047 potential in migraine and headache disorders
PharmNovo is pleased to announce that new preclinical research on PN6047 has been published in The Journal of Headache and Pain, adding to the growing body of scientific evidence supporting the potential of PN6047 beyond neuropathic pain.
The article, “PN6047 demonstrates preclinical efficacy in headache models as a novel delta-opioid receptor agonist,” reports efficacy across several validated preclinical headache models. The research was conducted in collaboration with Professor Amynah Pradhan and her team at Washington University School of Medicine.
The findings were first announced by PharmNovo in June 2026 and provide further insight into the potential of the unique pharmacological profile of PN6047 across additional indications. Publication in a peer-reviewed scientific journal provides further visibility and validation of these findings and supports the continued scientific evaluation of the broader therapeutic potential of PN6047.
Neuropathic pain remains the primary focus of the clinical development programme, with PN6047 advancing towards Phase IIa. At the same time, research in migraine and other headache disorders contributes to the expanding scientific foundation for the potential of PN6047 across multiple indications.
New publication in The Journal of Headache and Pain
PN6047 publication in The Journal of Headache and Pain strengthens PN6047 potential in migraine and headache disorders
PharmNovo is pleased to announce that new preclinical research on PN6047 has been published in The Journal of Headache and Pain, adding to the growing body of scientific evidence supporting the potential of PN6047 beyond neuropathic pain.
The article, “PN6047 demonstrates preclinical efficacy in headache models as a novel delta-opioid receptor agonist,” reports efficacy across several validated preclinical headache models. The research was conducted in collaboration with Professor Amynah Pradhan and her team at Washington University School of Medicine.
The findings were first announced by PharmNovo in June 2026 and provide further insight into the potential of the unique pharmacological profile of PN6047 across additional indications. Publication in a peer-reviewed scientific journal provides further visibility and validation of these findings and supports the continued scientific evaluation of the broader therapeutic potential of PN6047.
Neuropathic pain remains the primary focus of the clinical development programme, with PN6047 advancing towards Phase IIa. At the same time, research in migraine and other headache disorders contributes to the expanding scientific foundation for the potential of PN6047 across multiple indications.
Latest news
View all
Reports of broader therapeutic potential for PN6047
PharmNovo AB announces today new preclinical findings supporting the potential of PN6047 in migraine and opioid withdrawal syndrome. The findings were generated through the company's NIDA-funded collaboration with researchers at Washington University School of Medicine.
Read more
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
